BioSpace News Archive

100 percent of dollars raised by Pan-Mass Challenge riders to further advancements in cancer research and treatment

AscellaHealth, a specialty pharmacy benefit manager, serving commercial, Medicare and Medicaid segments, announces that Dea Belazi, president and CEO, AscellaHealth, will highlight proven strategies for optimizing the management of high-cost specialty diseases at the 6th Annual Cain Brothers Healthcare Conference, Oct. 23-24, Lotte New York Palace, 455 Madison Ave., New York, New York.

DURECT Corporation (Nasdaq: DRRX) announced today that the results from the recently completed Phase 2a study of DUR-928 in patients with alcoholic hepatitis (AH) have been selected for an oral presentation as part of the late-breaking session of The Liver Meeting® 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place on November 8-12, 2019, in Boston.

National conference for the American Society of Anesthesiologists, held at the Orange County Convention Center in Orlando, Florida, October 19-23.

Are there better ways to treat or mitigate PFAS—those fluorinated, organic substances that are of increasing public and regulatory concern?

C Spire executives and state medical leaders unveiled a new mobile app today that promises to improve access to quick, reliable health care for more people in Mississippi, especially those in rural and underserved areas, with minor ailments.

Senator William Brownsberger and State Representatives Jon Santiago and Dan Cullinane to Highlight Importance of Proper Drug Disposal

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2019 of $0.645 per share on outstanding common stock.

THINK Surgical, Inc. is pleased to announce the appointment of Paul Weiner as Chief Financial Officer (CFO), effective today, October 21, 2019.

INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune system to fight disease, announced today that Dr. Malú Tansey presented data that show the use of INmune Bio’s lead compound, XPro1595, appear to mitigate the exacerbation of Alzheimer’s-like pathology triggered by a high fat and high fructose diet in mice.